Biology will change the world. With it, we can feed, heal, and fuel people for generations to come. But enroute to these novel products, the research and development is complex, risky and costly. It requires highly skilled scientists and sophisticated equipment. Synthace maximises the productivity of both.
Synthace connects and automates laboratory and manufacturing equipment, vastly increasing efficiency of experimentation and the opportunity to innovate. It allows scientists to schedule experiments to run automatically, 24/7.
Whilst other industries have embraced computational advancements, the complexity and huge number of processes required in bioscience R&D has been very difficult to automate. Synthace’s software brings AI planning and automation to a range of different laboratory suppliers. By automating experimental processes across different pieces of equipment, they can build proprietary and sophisticated hardware stacks which allow scientists to be far more productive.
Founded in 2011 it has raised £65 million in capital to date, facilitating the development and deployment of a next generation operating system which links bioscience, computation and automation to exponentially improve productivity in bioscience.
With major pharma clients and operations in the EU and US, UKI2S has backed Synthace right from the start, supporting their mission to advance the Fourth Industrial Revolution to change the world for good.
The Synthace platform brings all the benefits of modern computing into the lab to re-imagine how we work with biology to create solutions for a healthier, more sustainable world.
Based on an open source, high level language written specifically for biologists, Synthace is designed to make simple, reproducible and scalable workflows that are easily automated and shared. Biologists around the world can now dramatically optimise biological experimentation and manufacturing processes to help turn biodesigns into desperately needed solutions for the challenges we face today.
capital raised to date
from founding
prevailing valuation
“At Synthace we want to give scientists the tools they need to spend time on what matters most; the science. With Synthace, we can help scientists to optimise experimentation, and bring promising, viable solutions to complex challenges faster. We’re thankful for the help we’ve had from UKI2S, offering us not only financial support, but the connections, resources, and expertise needed to bring our innovative technology to the global market.”
In 2014, UKI2S stepped in to support Synthace in its initial development of the platform. Along with three other venture capital syndicate members, and a group of angel investors, this funding round provided the UCL spin-out with an 18-month development runway.
Since then, we’ve introduced Synthace to some major industry players and customers, as well as key partners within robotics and laboratory instrumentation companies. With deals signed by majors companies like Merck and DOW AgroSciences, Synthace now serves customers across the pharmaceutical, agriscience and industrial biotechnology industries.
Innovation is borne from frustration and Synthace is an inspiring example of that. Having witnessed the benefits modern computing brought to other industries, this enterprising startup wanted to provide the same opportunities to bioscience.
With a Microsoft partnership that brought Synthace to the Azure Cloud, and recognition by the World Economic Forum as one of just thirty promising ‘Technology Pioneers 2016’ (and the only UK-based company on the list) Synthace’s potential to impact business and society through new technologies is undeniable – and limitless!
© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, t/a Midven, c/o WeWork, 55 Colmore Row, Birmingham, B3 2AA.
